Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Shares Outstanding (Weighted Average) (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Shares Outstanding (Weighted Average) data on record, last reported at $66.4 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 3.15% year-over-year to $66.4 million; the TTM value through Dec 2025 reached $66.4 million, up 3.15%, while the annual FY2025 figure was $66.4 million, 3.15% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $66.4 million in Q4 2025 per CLDX's latest filing, up from $66399.0 in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $66.4 million in Q4 2025 and bottomed at $42870.0 in Q4 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $15.0 million, with a median of $66156.5 recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 99.89% in 2022, then soared 103229.21% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $42870.0 in 2021, then rose by 9.37% to $46888.0 in 2022, then skyrocketed by 103229.21% to $48.4 million in 2023, then skyrocketed by 32.91% to $64.4 million in 2024, then increased by 3.15% to $66.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $66.4 million in Q4 2025, $66399.0 in Q3 2025, and $66392.0 in Q2 2025.